Published January 1, 2024
| Version v1
Journal article
Open
The use of autologous cell therapy in diabetic patients with chronic limb-threatening ischemia
Creators
- 1. Institut klinicke a experimentalni mediciny
- 2. First Faculty of Medicine, Charles University, 14021 Prague, Czech Republic
-
3.
Institute of Clinical and Experimental Medicine
- 4. Second Faculty of Medicine, Charles University, 15006 Prague, Czech Republic
- 5. Diabetes Center, Tameside and Glossop Integrated Care NHS Foundation Trust, Ashton-under-Lyne OL6 9RW, UK
- 6. Department of Endocrinology and Gastroenterology, University of Manchester, Manchester M13 9PL, UK
Description
Autologous cell therapy (ACT) is primarily used in diabetic patients with chronic limb-threatening ischemia (CLTI) who are not candidates for standard revascularization. According to current research, this therapy has been shown in some studies to be effective in improving ischemia parameters, decreasing the major amputation rate, and in foot ulcer healing. This review critically evaluates the efficacy of ACT in patients with no-option CLTI, discusses the use of mononuclear and mesenchymal stem cells, and compares the route of delivery of ACT. In addition to ACT, we also describe the use of new revascularization strategies, e.g., nanodiscs, microbeads, and epigenetics, that could enhance the therapeutic effect. The main aim is to summarize new findings on subcellular and molecular levels with the clinical aspects of ACT.
Notes
This research was supported by the National Institute for Research on Metabolic and Cardiovascular Diseases (Programme EXCELES, Project No. LX22NPO5104) funded by the European Union Next-Generation EU.
Files
ijms-25-10184_1.pdf
Files
(944.9 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:6b6f660899120bc57bbd70ba15997d6a
|
944.9 kB | Preview Download |
Additional details
Related works
- Has metadata
- 39337669 (PMID)
- Is part of
- 1661-6596 (ISSN)
- 1422-0067 (ISSN)
- References
- 10.3390/ijms251810184 (DOI)